Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsIndocoremedies

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to
    • Indoco Remedies Q1 PAT may dip 0.1% YoY to Rs 38.5 cr: Nirmal Bang

      Indoco Remedies Q1 PAT may dip 0.1% YoY to Rs 38.5 cr: Nirmal Bang

      Net Sales are expected to increase by 6.8 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs 435.9 crore, according to Nirmal Bang.

    • Indoco Remedies Q3 PAT seen up 46.1% YoY to Rs 482 cr: Nirmal Bang

      Indoco Remedies Q3 PAT seen up 46.1% YoY to Rs 482 cr: Nirmal Bang

      Net Sales are expected to increase by 18.3 percent Y-o-Y (down 2.2 percent Q-o-Q) to Rs 4,236 crore, according to Nirmal Bang.

    • Indoco Remedies Q1 PAT seen up 4.4% YoY to Rs 41.4 cr: Prabhudas Lilladher

      Indoco Remedies Q1 PAT seen up 4.4% YoY to Rs 41.4 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 5.1 percent Y-o-Y (down 0.6 percent Q-o-Q) to Rs 406.6 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q4 PAT seen up 52.9% YoY to Rs 38.2 cr: Prabhudas Lilladher

      Indoco Remedies Q4 PAT seen up 52.9% YoY to Rs 38.2 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 28.9 percent Y-o-Y (up 9.9 percent Q-o-Q) to Rs 393.4 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q3 PAT seen up 54.9% YoY to Rs 39.3 cr: Prabhudas Lilladher

      Indoco Remedies Q3 PAT seen up 54.9% YoY to Rs 39.3 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 17.1 percent Y-o-Y (up 0.6 percent Q-o-Q) to Rs 389.2 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q2 PAT seen up 53.9% YoY to Rs 38.6 cr: Prabhudas Lilladher

      Indoco Remedies Q2 PAT seen up 53.9% YoY to Rs 38.6 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 24.2 percent Y-o-Y (up 5.1 percent Q-o-Q) to Rs 400.5 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q3 PAT seen up 191.2% YoY to Rs. 9.3 cr: Prabhudas Lilladher

      Indoco Remedies Q3 PAT seen up 191.2% YoY to Rs. 9.3 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 17.7 percent Y-o-Y (up 3.4 percent Q-o-Q) to Rs. 283.4 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q1 PAT may dip 180.3% YoY to Rs. 9.6 cr: Prabhudas Lilladher

      Indoco Remedies Q1 PAT may dip 180.3% YoY to Rs. 9.6 cr: Prabhudas Lilladher

      Net Sales are expected to increase by 26.2 percent Y-o-Y (up 9.5 percent Q-o-Q) to Rs. 268.2 crore, according to Prabhudas Lilladher.

    • Indoco Remedies Q2 PAT may dip 42.5% YoY to Rs. 11.4 cr: ICICI Direct

      Indoco Remedies Q2 PAT may dip 42.5% YoY to Rs. 11.4 cr: ICICI Direct

      Net Sales are expected to decrease by 7.7 percent Y-o-Y (up 20.9 percent Q-o-Q) to Rs. 262.9 crore, according to ICICI Direct.

    • Indoco Remedies Q1 PAT may dip 24.24% YoY to Rs 15 cr: KR Choksey

      Indoco Remedies Q1 PAT may dip 24.24% YoY to Rs 15 cr: KR Choksey

      Net Sales are expected to increase by 0.41 percent Q-o-Q (up 5.54 percent Y-o-Y) to Rs 266.7 crore, according to KR Choksey. Indoco Remedies to report net profit at 15 crore down 24.24% year-on-year.

    • Indoco Remedies Q3 PAT seen up 3.4% to Rs 22.9 cr: KR Choksey

      Indoco Remedies Q3 PAT seen up 3.4% to Rs 22.9 cr: KR Choksey

      Net Sales are expected to increase by 5.3 percent Q-o-Q (up 14.5 percent Y-o-Y) to Rs 296 crore, according to KR Choksey.

    • Pharma companies revenues to rise 12% in Q3: Anand Rathi

      Pharma companies revenues to rise 12% in Q3: Anand Rathi

      Pharma companies are likely to post 12 percent Y-o-Y revenue growth. However, excluding Wockhardt (FDA issues) and Fortis Healthcare (divestments), revenue growth is expected to be 19 percent Y-o-Y.

    • See pharma sector's margins to dip 314 bps in 3QFY13: Angel

      See pharma sector's margins to dip 314 bps in 3QFY13: Angel

      Angel Broking has come out with earning expectations for pharmaceutical sector for the October-December quarter of 2012. The research firm expects the Indian pharma sector to post lackluster numbers for 3QFY2013 on the sales front.

    • Indoco Remedies Sept qtr PAT seen up at Rs 18cr: Angel

      Indoco Remedies Sept qtr PAT seen up at Rs 18cr: Angel

      Angel Broking has come out with its earning estimates on pharma sector for the quarter ended September 2011. According to the research firm, Indoco Remedies September quarter net sales are expected to go up by 12% at Rs 148 crore, year-on-year, (YoY) basis.

    • Indoco Remedies Dec qtr PAT seen up 60% at Rs 12.4cr: Angel

      Indoco Remedies Dec qtr PAT seen up 60% at Rs 12.4cr: Angel

      Angel Broking has come out with its earning estimates on the pharmaceutical sector for the quarter ended December 2010. According to the research firm, Indoco Remedies December quarter net sales are expected to go up by 27.2% to Rs 122 crore, Year-on-Year, (Y-o-Y) basis.

    • Indoco Remedies Dec qtr PAT seen up at Rs 12.9cr: Karvy

      Indoco Remedies Dec qtr PAT seen up at Rs 12.9cr: Karvy

      Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, Indoco Remedies December quarter sales are expected to go up by 28.8% at Rs 123.6 crore, Year-on-Year, (YoY) basis.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347